ERIS Lifesciences Ltd (ERIS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1002771,
    "name": "ERIS Lifescience",
    "stock_name": "ERIS Lifescience",
    "full_name": "ERIS Lifesciences Ltd",
    "name_url": "stocks-analysis/eris-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,459.50",
    "chg": 122.15,
    "chgp": "9.13%",
    "dir": 1,
    "prev_price": "1,337.35",
    "mcapval": "18,885.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 540596,
    "symbol": "ERIS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE406M01024",
    "curr_date": "May 20",
    "curr_time": "",
    "bse_nse_vol": "16.61 lacs",
    "exc_status": "Active",
    "traded_date": "May 20, 2026",
    "traded_date_str": "2026 05 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/eris-lifescience-1002771-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ERIS Lifesciences Q4 FY26: Tax Reversal Masks Operational Headwinds as Revenue Growth Decelerates",
        "link": "https://www.marketsmojo.com/news/result-analysis/eris-lifesciences-q4-fy26-tax-reversal-masks-operational-headwinds-as-revenue-growth-decelerates-4001594",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_quaterlyResult_4001594.png",
        "date": "2026-05-20 20:17:22",
        "description": "ERIS Lifesciences Ltd., a speciality pharmaceutical company focused on chronic therapies, reported a consolidated net profit of ₹281.61 crores for Q4 FY26, marking an extraordinary 200.10% year-on-year surge and a striking 182.40% sequential jump. However, this headline-grabbing performance was largely driven by a significant tax reversal of ₹119.69 crores rather than operational excellence, raising questions about the sustainability of earnings momentum. The stock surged 9.13% to ₹1,459.50 following the results announcement, though it remains 23.57% below its 52-week high of ₹1,909.55."
      },
      {
        "title": "ERIS Lifesciences Ltd Surges 8.32% to Day's High of Rs 1458 — Outperforms Sector by 8.15 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-hits-intraday-high-with-832-surge-on-20-may-2026-4001193",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_priceRelatedfactors_4001193.png",
        "date": "2026-05-20 15:01:22",
        "description": "The Sensex edged up 0.26% after a volatile session, but ERIS Lifesciences Ltd outpaced the broader market with an 8.32% gain, reaching an intraday high of Rs 1458. This 8.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-4000705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_4000705.png",
        "date": "2026-05-20 10:10:56",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3990343",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_3990343.png",
        "date": "2026-05-14 08:00:48",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of early February 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player differently against its peers and historical benchmarks."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3982747",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_mojoScore_3982747.png",
        "date": "2026-05-09 10:10:36",
        "description": "ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-growing-price-pressure-amid-sector-comparisons-3974669",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ERISLifescience_valuationdot_3974669.png",
        "date": "2026-05-05 08:01:25",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex."
      },
      {
        "title": "ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3967388",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_valuationdot_3967388.png",
        "date": "2026-04-29 08:00:46",
        "description": "ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages."
      },
      {
        "title": "ERIS Lifesciences Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/eris-lifesciences-ltd-is-rated-sell-3966332",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_mojoScore_3966332.png",
        "date": "2026-04-28 10:10:55",
        "description": "ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/eris-lifesciences-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3960144",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ERISLifescience_technicaldot_3960144.png",
        "date": "2026-04-24 08:03:17",
        "description": "ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges."
      }
    ],
    "total": 320,
    "sid": "1002771",
    "stock_news_url": "https://www.marketsmojo.com/news/eris-lifesciences-1002771"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "15-May-2026",
      "details": "As Attached",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend",
      "datetime": "15-May-2026",
      "details": "Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 inter alia to consider and approve Financial Results and Interim Dividend",
      "source": "BSE"
    },
    {
      "caption": "Credit Rating Of Eris Threpeutics Limited",
      "datetime": "12-May-2026",
      "details": "As Attached",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ERIS Lifesciences Ltd has declared <strong>735%</strong> dividend, ex-date: 13 Feb 25",
          "dt": "2025-02-13",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

ERIS Lifesciences Q4 FY26: Tax Reversal Masks Operational Headwinds as Revenue Growth Decelerates

2026-05-20 20:17:22

ERIS Lifesciences Ltd., a speciality pharmaceutical company focused on chronic therapies, reported a consolidated net profit of ₹281.61 crores for Q4 FY26, marking an extraordinary 200.10% year-on-year surge and a striking 182.40% sequential jump. However, this headline-grabbing performance was largely driven by a significant tax reversal of ₹119.69 crores rather than operational excellence, raising questions about the sustainability of earnings momentum. The stock surged 9.13% to ₹1,459.50 following the results announcement, though it remains 23.57% below its 52-week high of ₹1,909.55.

Read full news article

ERIS Lifesciences Ltd Surges 8.32% to Day's High of Rs 1458 — Outperforms Sector by 8.15 Percentage Points

2026-05-20 15:01:22

The Sensex edged up 0.26% after a volatile session, but ERIS Lifesciences Ltd outpaced the broader market with an 8.32% gain, reaching an intraday high of Rs 1458. This 8.15-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-05-20 10:10:56

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-05-14 08:00:48

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade as of early February 2026. This change reflects evolving market perceptions amid fluctuating price-to-earnings (P/E) and price-to-book value (P/BV) ratios, positioning the small-cap pharmaceutical player differently against its peers and historical benchmarks.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-05-09 10:10:36

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Growing Price Pressure Amid Sector Comparisons

2026-05-05 08:01:25

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, as reflected in its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change has prompted a downgrade in its Mojo Grade from Hold to Sell, signalling increased caution among investors despite the company’s solid operational metrics and long-term returns outperforming the Sensex.

Read full news article

ERIS Lifesciences Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-04-29 08:00:46

ERIS Lifesciences Ltd has seen a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade, signalling improved price attractiveness for investors. Despite recent headwinds reflected in its share price performance, the company’s relative valuation metrics now present a more balanced risk-reward profile compared to its pharmaceutical peers and historical averages.

Read full news article

ERIS Lifesciences Ltd is Rated Sell

2026-04-28 10:10:55

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

ERIS Lifesciences Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-04-24 08:03:17

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, as reflected in recent indicator readings. Despite a 3.07% gain on 24 Apr 2026, the stock’s technical parameters present a complex picture, with mixed signals from MACD, RSI, moving averages, and other key indicators, suggesting cautious optimism amid underlying challenges.

Read full news article

View All News